Tumor-induced apoptosis of T lymphocytes: Elucidation of intracellular apoptotic events

Blood

Volumn 95, Issue 6, 2000, Pages 2015-2023

  Gastman, Brian R ^a   Johnson, Daniel E ^a   Whiteside, Theresa L ^a   Rabinowich, Hannah ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; INTERLEUKIN 1BETA CONVERTING ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; ARTICLE; CELL DEATH; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIGAND BINDING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

EID: 0034653462     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.6.2015     Document Type: Article

References (73)

1. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075.
2. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A. 1997;94:6420.
3. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med. 1997;2:1361.
4. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996; 274:1363.
5. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest. 1997;99:1173.
6. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997;158:4521.
7. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57:1007.
8. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes. J Clin Invest. 1998;101:2579.
9. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res. 1998; 58:2057.
10. Gratas C, Tohma Y, Van Meir EG, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997;7:863.
11. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res. 1999;5: 1219.
12. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immmunother. 1998; 21:295.
13. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. Human melanoma cells do not express Fas (ADO-1/CD95) ligand. Cancer Res. 1999;59:59.
14. Chappell DB, Restifo NP. T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother. 1998; 47:65.
15. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995; 181:71.
16. Matiba B, Mariani SM, Krammer PH. The CD95 system and the death of a lymphocyte. Semin Immunol. 1997;9:59.
17. Eischen CM, Williams BL, Zhang W, et al. ZAP-70 tyrosine kinase is required for the up-regulation of Fas ligand in activation-induced T cell apoptosis. J Immunol. 1997;159:1135.
18. Katsikis PD, Garcia-Ojeda ME, Totres-Roca JF, et al. Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med. 1997;186: 1365.
19. Martinez-Lorenzo MJ, Alava MA, Gamen S, et al. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol. 1998;28:2714.
20. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1:543.
21. Wu GS, Burns TF, McDonald ER, et al. Killer/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141.
22. Yanagisawa K, Osada H, Masuda A, et al. induction of apoptosis by Smad3 and down-regulation of Smard3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene. 1998;17:1743.
23. Hirata H, Takahashi A, Kobayashi S, et al. Caspases are activated in a branched proteases cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 1998;187:587.
24. Martins LM, Mesner PW, Kottke TJ, et al. Comparison of caspase activation and sub-cellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood. 1997;90: 4283.
25. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91:443.
26. Pan GH, O'Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem. 1998;273:5841.
27. Datta R, Kojima H, Banach D, et al. Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem. 1997;272:1965.
28. Dorstyn L, Kumar S. Differential inhibitory effects of CrmA, p35, IAP and three mammalian IAP homologues on apoptosis in NIH3T3 cells following various death stimuli. Cell Death Differ. 1997;4: 570.
29. Woo M, Hakem R, Soengas MS, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 1998;12:806.
30. Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J. 1997;16:2271.
31. Heo DS, Snyderman C, Gollin SM, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 1989;49:5167.
32. Dou QP, An B, Antoku K, Johnson DE. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J Cell Biochem. 1997;64:586.
33. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 1997;27:1.
34. Koning AJ, Lum PY, Williams JM, Wright R. DIOC6 staining reveals organelle structure and dynamics in living yeast cells. Cell Motil Cytoskeleton. 1993;25:111.
35. Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/Apo-1/CD95- and ceramide-induced apoptosis. J Exp Med. 1997;186:25.
36. Rabinowich H, Manciulea M, Metes M, et al. Physical and functional association of Fcμ receptor on human NK cells with the ζ and Fc∈RI-γ chains and with src-family protein tyrosine kinases. J Immunol. 1996;157:1485.
37. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1.
38. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci. 1997;22:299.
39. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37.
40. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem. 1998;273:32,608.
41. Packard BZ, Komoriya A, Toptygin DD, Brand L. Structural characteristics of fluorophores that form intramolecular H-type dimers in a protease substrate. J Phys Chem. 1997;101:5070.
42. Packard BZ, Toptygin DD, Komoriya A, Brand L. Intramolecular resonance dipole-dipole interactions in a profluorescent protease substrate. J Phys Chem. 1998;102:752.
43. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/ APO-1) death-inducing signaling complex. Cell. 1996;85:817.
44. Muzio M, Salvesen GS, Dixit VM. FLICE induced apoptosis in a cell-free system: cleavage of caspase zymogens. J Biol Chem. 1997;272:2952.
45. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559.
46. Fernandes-Alnemri T, Armstrong RC, Krebs J, et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A. 1996;93:7464.
47. Cheng EH-Y, Kirsh DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 1997;278:1966.
48. Hirsch T, Marchetti P, Susin SA, et al. The apoptosis-necrosis paradox: apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene. 1997;15:1573.
49. Margolin N, Raybuck SA, Wilson KP, et al. Substrate and inhibitor specificity of interleukin-1 beta-converting enzyme and related caspases. J Biol Chem. 1997;272:7223.
50. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Caspase mediated degradation of TcR-ζ chain. Cancer Res. 1999;59:1422.
51. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613.
52. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alteration in expression and function of signal transducing protains in tumor-associated T and NK cells in patients with ovarian carcinoma. Clin Cancer Res. 1996;2:161.
53. Grandgirard D, Studer E, Monney L, et al. Alpha-viruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivalion of Bcl-2, EMBO J. 1998;17:1268.
54. Horiguchi S, Petersson M, Nakazawa T, et al. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res. 1999;59:2950.
55. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998;160:5669.
56. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol. 1998;10:564.
57. Barge RM, Willemze R, Vandenabeele P, Fiers W, Beyaert R. Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal. FEBS Lett. 1997;409:207.
58. Antoku K, Liu Z, Johnson DE. IL-3 withdrawal activates a CrmA-insensitive poly(ADP-ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells. Leukemia. 1998;12:682.
59. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS. Target protease specificity of the viral serpin Crma: analysis of five caspases. J Biol Chem. 1997;272:7797.
60. Takahashi A, Hirata H, Yonehara S, et al. Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8. Oncogene. 1997;14: 2741.
61. Reed JC. Double identity for proteins of the Bcl-2 family. Nature. 1997;387:773.
62. Kluck RM, Bossywetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132.
63. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta. 1998;1366:127.
64. Li F, Srinivasan A, Wang Y, Armstrong RC, Tomaselli KJ, Fritz LC. Cell-specific induction of apoptosis by microinjection of cytochrome c: Bcl-X(L) has activity independent of cytochrome c release. J Biol Chem. 1997;272:30.299.
65. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A. 1998;95:4386.
66. Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 1998;391:496.
67. Medema JP, Scaffidi C, Krammer PH, Peter ME. Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J Biol Chem. 1998;273:3388.
68. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998; 17:1675.
69. Strasser A, Harris AW, Huang DC, Krammer PH. Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995;14:6136.
70. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A. 1996;93: 2239.
71. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491.
72. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481.
73. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem. 1999;274:1156.